'Non-criteria antiphospholipid antibodies': bridging the gap between seropositive and seronegative antiphospholipid syndrome

Simona Truglia, Silvia Mancuso, Antonella Capozzi, Serena Recalchi, Gloria Riitano, Agostina Longo, Sara De Carolis, Francesca Romana Spinelli, Cristiano Alessandri, Fulvia Ceccarelli, Caterina De Carolis, Roberta Misasi, Maurizio Sorice, Fabrizio Conti, Francesco Conti

Risultato della ricerca: Contributo in rivistaArticolo in rivista


OBJECTIVE: We aimed to analyse the prevalence of non-criteria anti-phospholipid (aPL) antibodies and their role in the diagnosis, treatment and prognosis in a cohort of patients with clinical features consistent with a diagnosis of antiphospholipid syndrome (APS), but persistently negative for criteria aPL - anti-cardiolipin antibodies (aCL), anti-β2-glycoprotein I antibodies (aβ2-GPI) and lupus anticoagulant (LA) - named seronegative APS (SN-APS). METHODS: Sera from SN-APS patients were tested for aCL by TLC-immunostaining, anti-vimentin/cardiolipin (aVim/CL) and anti-phosphatidylserine/prothrombin (anti-PS/PT) by ELISA. Control groups of our study were APS patients and healthy controls. RESULTS: We enrolled 114 consecutive SN-APS patients, 69 (60.5%) resulted positive for at least one non-criteria test in two occasions 12 weeks apart. Among the persistently positive patients to these tests, 97% resulted positive for aCL by TLC-immunostaining, 52.3% for aVim/CL and 17.4% for aPS/PT. SN-APS patients with double positivity (aCL by TLC-immunostaining and aVim/CL) showed a likelihood positive ratio of 8 to present mixed thrombotic and obstetrical features. Among SN-APS patients tested positive, after the therapeutic changes, three cases of recurrent thrombosis were observed [median follow-up 41 months (IQR 39.5)]. Twenty pregnancies were recorded in 17 SN-APS patients after the detection of unconventional aPL and 12 of them (60%) experienced a good outcome under conventional treatment for APS. CONCLUSIONS: This is the largest monocentric study demonstrating that aCL tested by TLC-immunostaining and aVim/CL can detect aPL positivity in SN-APS. It may encourage clinicians to monitor and provide adequate targeted therapy, which improve SN-APS prognosis.
Lingua originaleEnglish
pagine (da-a)826-833
Numero di pagine8
Stato di pubblicazionePubblicato - 2022


  • Adult
  • Antibodies, Antiphospholipid
  • Antiphospholipid Syndrome
  • Cardiolipins
  • Case-Control Studies
  • Chromatography, Thin Layer
  • Enzyme-Linked Immunosorbent Assay
  • Female
  • Humans
  • Male
  • Middle Aged
  • Phosphatidylserines
  • Prognosis
  • Prothrombin
  • SN-APS
  • TLC-immunostaining
  • Vimentin
  • aVim/CL
  • antiphospholipid syndrome
  • beta 2-Glycoprotein I
  • prognosis


Entra nei temi di ricerca di ''Non-criteria antiphospholipid antibodies': bridging the gap between seropositive and seronegative antiphospholipid syndrome'. Insieme formano una fingerprint unica.

Cita questo